Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on HeraMED.
RELATED STOCKHEAD STORIES
Tech
ASX Tech Stocks: ESG platform Envirosuite (ASX:EVA) up 8.33% with plans to accelerate US growth
Health & Biotech
HeraMED signs paid pilot with Obstetrix Medical Group, providers of care and diagnostics to 1 in 4 babies born in US
News
April Winners Column: Resources re-takes the mantle, led by one stock that gained nearly 500pc
Health & Biotech
HeraMED secures landmark commercial agreement with Joondalup Health Campus
Health & Biotech
Heart disease is becoming a bigger problem but these ASX stocks are trying to help with it
Health & Biotech
Leading scientific publication backs HeraMED’s foetal heartbeat monitor
Health & Biotech
Altor Capital has high conviction on these 4 medtech plays for 2021
Health & Biotech
Why HeraMED’s HeraBEAT device could replace CTG machines in emerging economies
Health & Biotech
Mayo Clinic approves clinical study of HeraMED’s HeraBEAT device
Health & Biotech
HeraMED taps into US employee benefit industry with Teleperinatal pilot
News
10 at 10: These ASX stocks have found their voice this morning
Health & Biotech
HeraMED taps into US healthcare market with eCare21 partnership
Stockhead TV
Health tech plays are seeing tectonic shifts in customer growth
Health & Biotech
Successful clinical study for HeraBEAT device showcases its telehealth application
Health & Biotech
HeraMED breaks into US healthcare market with eCare21 partnership
Health & Biotech
Here’s what the telehealth industry wants from ScoMo to maintain momentum
Health & Biotech
